Skip to main content
Anteris Technologies Global Corp. logo

Anteris Technologies Global Corp. — Investor Relations & Filings

Ticker · AVR ISIN · US03675P1021 ASX Manufacturing
Open in API
Filings indexed 1,665 across all filing types
Latest filing 2016-07-10 Investor Presentation
Country US United States of America
Listing ASX AVR

About Anteris Technologies Global Corp.

https://anteristech.com/

Anteris Technologies is a structural heart company focused on the development and commercialization of medical devices for heart valve disease. Its lead product is the DurAVR® Transcatheter Heart Valve (THV), a biomimetic valve designed for patients with severe aortic stenosis. The DurAVR® THV is engineered to mimic the performance of a healthy human aortic valve, aiming to restore normal, laminar blood flow. Clinical studies have shown the device delivers a favorable hemodynamic profile, characterized by low pressure gradients and a significant reduction in prosthesis-patient mismatch (PPM), even in patients with challenging anatomies. The company is advancing its technology through pivotal clinical trials to establish a new standard in transcatheter aortic valve replacement (TAVR) and improve long-term patient outcomes.

Recent filings

Filing Released Lang Actions
Admedus Investor Webinar 29 pages 1.4MB
Investor Presentation Classification · 95% confidence The document is titled 'Admedus Investor Webinar' and dated July 11, 2016. It contains a detailed presentation overview including company strategy, commercial operations, global organization structure, financial review, clinical and R&D programs, manufacturing, and a summary with strategic outlook. The content is structured as a presentation with slides and speaker notes, typical of investor presentations. There is no indication that this is a transcript of a call, an annual or quarterly report, or a regulatory filing. The document is lengthy (over 14,000 characters) and contains detailed strategic and financial information aimed at investors. Therefore, it fits the definition of an Investor Presentation (IP).
2016-07-10 English
Admedus to Host Investor Webinar 2 pages 210.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX release announcing an upcoming investor webinar to discuss the results of a recent company review and future direction. It includes details about the webinar date, time, registration link, and contact information. There is no substantive financial data, detailed financial statements, or comprehensive report content. The document is short (3273 characters) and serves as an announcement for an event rather than a full report or detailed presentation. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Investor Presentation. It is primarily an announcement of an investor event, which aligns best with Regulatory Filings (RNS) as a general regulatory announcement and miscellaneous filing category.
2016-07-05 English
Appendix 3B 14 pages 1.0MB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 3B form submitted to the Australian Stock Exchange (ASX) by Admedus Ltd. It details the issuance of 250,000 unlisted options to employees under an Employee Share Option Plan, including terms, allotment dates, and compliance with ASX Listing Rules. The document is a formal announcement of a capital raising event involving new securities issuance and application for quotation of these securities on the ASX. It is not a financial report, earnings release, or management discussion, but rather a regulatory announcement about capital structure changes and securities issuance. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2016-06-28 English
Chairman's Letter to Shareholders 2 pages 451.2KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement containing a letter from the Chairman to shareholders. It discusses management changes, a global restructuring initiative, and plans to report back to the market via a shareholder webinar. The document is relatively short (4147 characters) and does not contain detailed financial statements or comprehensive financial data. It is primarily an update and communication to shareholders rather than a full report or detailed financial disclosure. There is no indication that this is a full Annual Report, Interim Report, or Earnings Release. It is also not a regulatory certification or a voting result announcement. Given the nature of the content and length, this fits best as a Regulatory Filing (RNS), which is a general regulatory announcement and a fallback category for miscellaneous filings that do not fit other specific categories.
2016-06-06 English
Initial Director's Interest Notice 2 pages 339.2KB
Regulatory Filings
2016-05-29 English
Admedus Appoints New Board Director 2 pages 354.9KB
Board/Management Information Classification · 100% confidence The document is a company announcement from Admedus Ltd dated May 27, 2016, regarding the appointment of a new board director, Mr. Mathew Ratty. It details his background, qualifications, and expected contributions to the company. There is no financial data, report, or regulatory filing referenced beyond this appointment. The content clearly fits the category of announcing changes in the company's board of directors. The document length is 3397 characters, which is consistent with a typical announcement rather than a full report. Therefore, the appropriate classification is Board/Management Information (MANG).
2016-05-26 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.